Status and phase
Conditions
Treatments
About
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Hodgkin's or non-Hodgkin's Lymphoma.
≥ 1 prior therapy and currently requiring therapy.
Evaluable disease (defined by disease-specific criteria listed in Appendix 1)
≥ 18 years of age.
ECOG performance score ≤ 2 (see Appendix 2).
Life-expectancy ≥ 2 months.
Written informed consent in compliance with ZIOPHARM policies and the Human Investigation Review Committee with jurisdiction over the site.
No anti-cancer therapy exception of hydroxyurea ≤ 3 weeks before Baseline (Day 1, Cycle 1).
The following clinical laboratory values < 2 weeks before Baseline:
Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
50 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal